BioProgress gains EU accreditation for SoluPol application
16 August 2007
BioProgress, the specialty pharmaceutical and healthcare company has received Medical Device approvals from an EU Notified Body for two novel line extensions of the Artisial / Hypozalix xerostomia (dry mouth) treatment using SoluPol technology.
This regulatory approval equates to authorisation to sell the products to the general public in Europe and certain other markets such as South America and the Middle East.
Richard Trevillion, Chief Executive Officer, BioProgress said:
'Once again this accreditation demonstrates the strength of the Company's development pipeline. We are continually proving our ability to apply our enabling technologies to make products that reach the market and are able to deliver revenues which further increase shareholder value.'
|
Relevant Companies
For more Company information and share price data click below:
|